Ribomic

Ribomic Net Debt / EBITDA

The Net Debt to EBITDA of Ribomic (4591.T) as of Oct 30, 2026 is 2.42. In the previous year, Net Debt to EBITDA was 2.71 — a change of -10.74% (lower).

Net Debt / EBITDA

2.42

YoY

-10.74%

Last updated:

Net Debt to EBITDA of Ribomic is 2023 2.42 . Net Debt to EBITDA of Ribomic was 2022 2.71 . It decreases by -10.74% lower compared to the previous year.

The Ribomic Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2011
2.48 JPY
Jan 1, 2017
3.04 JPY
Jan 1, 2018
2.43 JPY
Jan 1, 2019
1.53 JPY
Jan 1, 2020
2.19 JPY
Jan 1, 2021
4.81 JPY
Jan 1, 2022
2.71 JPY
Jan 1, 2023
2.42 JPY
The Ribomic Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
2.42-10.74%
2.71-43.62%
4.81+119.71%
2.19+43.53%
1.53-37.14%
2.43-20.10%
3.04+22.56%
2.48+76.39%
1.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Net Debt to EBITDA of Ribomic is 2.42 in 2023.

Net Debt to EBITDA of Ribomic changed from 2.71 to 2.42, representing a -10.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Ribomic since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Ribomic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ribomic

All Key Metrics — Ribomic